吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

何志高; 鲍思蔚; 翟晓波

doi:10.3969/j.issn.1006-0111.2012.02.015

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

上海市东方医院药学部, 上海 200120

基金项目: "浦东新区卫生系统医学领先人才培训项目"(PWRd2007-12)资助.

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

摘要: 目的利用Meta分析评价吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的有效性与安全性。方法检索Pubmed数据库和CHKD数据库,纳入随机对照试验,用专用软件Review Manager Version4.2.2进行系统评价。结果共有7个英文期刊文献研究1 561例患者,10个中文期刊文献研究864例患者纳入系统评价。英文期刊文献Meta分析结果显示吉西他滨+顺铂方案与长春瑞滨+顺铂方案在总缓解率上无区别,在一年生存率上吉西他滨+顺铂方案方案优于长春瑞滨+顺铂方案,中文期刊文献Meta分析结果显示两套方案在总缓解率和一年生存率上均无显著性差异。关于毒性反应方面的报道,中英文期刊文献Meta分析结果一致,吉西他滨+顺铂方案中性粒细胞减少发生率低于长春瑞滨+顺铂方案,血小板减少发生率高于长春瑞滨+顺铂方案,恶心呕吐发生率差异无统计学意义。结论中英文期刊文献在评价吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的有效性上有区别。应重视提高中文期刊随机对照研究文献的质量,同时在晚期非小细胞肺癌治疗过程中,应结合患者具体情况,选择对患者生活质量影响较小的方案。
- 晚期非小细胞肺癌 /
- 化学治疗 /
- 吉西他滨 /
- 长春瑞滨 /
- 顺铂 /
- Meta分析
Abstract: Objective To compare and evaluate the effectiveness and security of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer by Meta-analysis. Methods PubMed database and CHKD database were searched, included in randomized controlled trials. Special software Review Manager Version 4.2.2 was used to systematic reviews. Results Seven studies of English journals involving 1 561 patients and ten studies of Chinese journals involving 864 patients were included. There was no difference in the overall response from gemcitabine versus vinorelbine in combination with cisplatin by Meta-analysis of English and Chinese journals. But the project of gemcitabine+cisplatin was superior to vinorelbine+cisplatin in 1-year survival rate of English journals and there was no difference in 1-year survival rate by Meta-analysis of Chinese journals. Both English and Chinese journals showed the same reports of toxicity. The incidence rate of neutropenia was higher in vinorelbine+cisplatin, and the thrombocytopenia was higher in gemcitabine + cisplatin, nausea and vomiting and nervous system response were no significant difference between two groups. Conclusions The effectiveness of gemcitabine versus vinorelbine combined with cisplatin of advanced non-small cell lung cancer was different. Improving the quality of RCT in Chinese journals was very important.
- advanced non-small cell lung cancer /
- chemotherapy /
- gemcitabine /
- vinorelbine /
- cisplatin /
- Meta-znalysis

[1]	Novello S,Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1 :Early-stage disease[J].Oncol (Williston Park),2003,17(3):357.
[2]	Alberti W.Chemotherapy in non-small-cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomized clinical trials Non-small Cell Lung Cancer Collaborative Group[J].BMJ,1995,311(7010):899.
[3]	Juni P, Altman DG, Egger M.Systematic reviews in health care: Assessing the quality of controlled clinical trials[J].BMJ,2001,323(7303):42.
[4]	Chang JW,Tsao TC,Yang CT,et al.A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer[J].Chang Gung Med J,2008,31(6):559.
[5]	Comeplla P, Frasci G, Panza N, et al.Randomized trial comparing cisplatin,gemcitabine,and vinorelbine in advanced non-small-cell lung cancer:interim analysis of a phase Ⅲ trial of the Southern Italy Cooperative Oncology Group[J].J Clin Oncol,2000,18(7):1451.
[6]	Gebbia V,Galetta D, Caruso M,et al.Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage ⅢB-Ⅳ non small cell lung carcinoma:a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale[J].Lung Cancer,2003,9(2):179.
[7]	Gridelli C,Maione P,Illiano A,et al.Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer:the MILES-2P studies[J].J Clin Oncol,2007,25(29):4663.
[8]	Martoni A, Marino A,Sperandi F,et al.Multicentre randomised phase Ⅲ study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer[J].Eur J Cance,2005,1(1):81.
[9]	Novello S,Kielhorn A,Stynes G,et al.Cost-minimisation analysis comparing gemcitabine/cisplatin,paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment advanced non-small cell lung cancer in Italy[J].Lung Cancer,2005,48(3):379.
[10]	Ohe Y,Ohashi Y,Kubota K,et al.Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2):317.
[11]	岳峥,李琳琳.GP方案和NP方案治疗晚期非小细胞肺癌疗效比较[J].实用肿瘤学杂志,2006,20(4):315.
[12]	张英.长春瑞滨联合顺铂治疗晚期非小细胞肺癌的疗效观察[J].临床肺科杂志,2011,16(11):1729.
[13]	时珠海.以顺铂为基础三种化疗方案治疗晚期非小细胞肺癌疗效观察[J].内科,2011,6(4):321.
[14]	赵文英,吉兆宁.顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究[J].中国临床药理学与治疗学,2006,11(12):1408.
[15]	刘联,王秀问,黎莉,等.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990.
[16]	陈群,石琴,谢强,等.不同方案治疗晚期非小细胞肺癌的近期疗效观察[J].临床肺科杂志,2008,13(8):998.
[17]	宋昱晨.GP与NP方案治疗晚期非小细胞肺癌的临床对比观察[J].当代医学,2007,(10):68.
[18]	谢强,陈群,李育宏,等.GP和NP方案治疗晚期非小细胞肺癌的随机对照临床研究[J].临床肺科杂志,2008,13(2):160.
[19]	李兆元,黄秋华,徐海声,等.国产吉西他滨或长春瑞滨联合顺铂治疗进展期非小细胞肺癌的临床观察[J].现代肿瘤医学,2007,15(9):1255.
[20]	隋捷,刘积良,段寅,等.吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床,2004,31(23):1349.
[21]	胡燕,徐传新.缬沙坦治疗轻、中度原发性高血压有效性与安全性的Meta分析 [J].中国药房,2008,19(2):128.
[22]	何志高,周东,舒丽芯.荟萃分析在头孢三嗪治疗下呼吸道感染中的应用[J].中国药房,2001,12(5):280.
[23]	林晓萍,王庆生.Meta-analysis在肿瘤循证医学中的应用[J].中国肿瘤临床(英文版),2008,5(1):1.

[1]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
[2]	陈晓芸, 赵旭, 曾位位. 艾普拉唑肠溶片用于治疗反流性食管炎的有效性及安全性Meta分析 . 药学实践与服务, 2023, 41(7): 443-448. doi: 10.12206/j.issn.2097-2024.202111080
[3]	熊明彪, 曹辉, 杨德钱. 连花清瘟胶囊对比奥司他韦治疗流行性感冒疗效和安全性的Meta分析 . 药学实践与服务, 2021, 39(5): 454-459. doi: 10.12206/j.issn.1006-0111.202012021
[4]	费舒扬, 赵力, 孙琳, 张蓉, 李晶, 葛长江. 植入药物洗脱支架后短期与长期双联抗血小板疗效比较的Meta分析 . 药学实践与服务, 2020, 38(1): 81-87. doi: 10.3969/j.issn.1006-0111.201907135
[5]	姚囡囡, 林莉莉, 黄珊, 付文倩, 宋洪涛. 312例吉西他滨的不良反应分析 . 药学实践与服务, 2020, 38(2): 174-178. doi: 10.3969/j.issn.1006-0111.201905052
[6]	阮军, 尹恒, 寇国先, 刘茗心, 杨蕊西. 异甘草酸镁治疗抗结核药物所致肝损伤疗效的Meta分析 . 药学实践与服务, 2019, 37(4): 375-379. doi: 10.3969/j.issn.1006-0111.2019.04.018
[7]	林莉莉, 张妍, 刘志宏, 吴珏, 宋洪涛. 酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析 . 药学实践与服务, 2019, 37(3): 268-273. doi: 10.3969/j.issn.1006-0111.2019.03.016
[8]	林莉莉, 黄爱文, 林美钦, 方婕, 沈钦勇, 宋洪涛. 替吉奥单药或联合铂类治疗晚期非小细胞肺癌患者疗效与安全性的Meta评价 . 药学实践与服务, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
[9]	吴思凡, 谭长宇, 樊红彬, 印晓星, 鲁茜. 奥卡西平和卡马西平治疗脑卒中后继发性癫痫疗效与安全性的Meta分析 . 药学实践与服务, 2018, 36(4): 373-378. doi: 10.3969/j.issn.1006-0111.2018.04.020
[10]	朱文玉, 姜齐, 张亮, 吴涓, 王洁, 丁红梓. 晚期非小细胞肺癌两种一线化疗方案的疗效观察和药物经济学分析 . 药学实践与服务, 2018, 36(2): 176-179. doi: 10.3969/j.issn.1006-0111.2018.01.017
[11]	韦忠明, 莫冬海, 黄启斌, 丁雪鹰. 吉西他滨温敏凝胶注射剂的制备及其含量测定 . 药学实践与服务, 2016, 34(1): 36-40. doi: 10.3969/j.issn.1006-0111.2016.01.010
[12]	纪松岗, 吴琼, 朱臻宇, 董昕, 洪战英, 柴逸峰. 左卡尼汀缓解顺铂造成急性肾损伤的血清代谢组学研究 . 药学实践与服务, 2015, 33(5): 429-433. doi: 10.3969/j.issn.1006-0111.2015.05.012
[13]	寇晓霞, 丁永梅, 黄耀, 袁振刚, 钱其军. 吉西他滨对胰腺癌外周血调节性T细胞影响的研究 . 药学实践与服务, 2015, 33(3): 258-260,268. doi: 10.3969/j.issn.1006-0111.2015.03.018
[14]	蔡和平, 王卓. 拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析 . 药学实践与服务, 2014, 32(1): 23-26,30. doi: 10.3969/j.issn.1006-0111.2014.01.006
[15]	黄秋明, 涂雪松, 晏琼, 史传林. 马来酸桂哌齐特治疗糖尿病周围神经病变的Meta分析 . 药学实践与服务, 2012, 30(2): 137-142. doi: 10.3969/j.issn.1006-0111.2012.02.016
[16]	何志高, 严俊, 陈国涵, 鲍思蔚, 翟晓波, 金丽, 施燕. 长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌的成本效用研究 . 药学实践与服务, 2012, 30(6): 462-463,480. doi: 10.3969/j.issn.1006-0111.2012.06.020
[17]	张琪, 夏爱军. 重组人血管内皮抑制素联合化疗治疗非小细胞肺癌疗效的Meta分析 . 药学实践与服务, 2010, 28(6): 451-455.
[18]	孙德好, 邵凌, 刘胜, 陈森林, 曹晓冰. 依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察 . 药学实践与服务, 2009, 27(3): 189-192.
[19]	张美和, 黄成华, 丁晓虎, 沈晓琴, 韩竹俊. 国产加替沙星与左氧氟沙星双盲随机对照治疗细菌感染的Meta分析 . 药学实践与服务, 2006, (6): 346-351.
[20]	任宏斌, 魏红. 金属配合物抗癌药物研究 . 药学实践与服务, 2001, (2): 117-119.

点击查看大图

计量

文章访问数: 3268
HTML全文浏览量: 239
PDF下载量: 354
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

计量

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

上海市东方医院药学部, 上海 200120

English Abstract

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

全文HTML

目录

留言板

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

计量

出版历程

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

上海市东方医院药学部, 上海 200120

English Abstract

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

全文HTML

目录